ClinicalTrials.gg
RecruitingNCT06724289Updated Jun 23, 2026

Psilocybin for Prolonged Grief Disorder

An Early Phase 1 interventional study of Psilocybin 25 mg and Functional Magnetic Resonance Imaging (fMRI) in Prolonged Grief Disorder, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by University of Virginia · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prolonged Grief Disorder with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Prolonged Grief Disorder · United States.

Planned enrollment
12th of 14
12 · median 42
Started
2026
with 1 other
Phase 1
2 of 15
1 open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
University of Virginia

Among the 15 studies in Prolonged Grief Disorder with a site in United States, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 11th registered.

Prolonged Grief Disorder

40 studies on the registry are indexed under Prolonged Grief Disorder; 14 are open to participants now.

Browse Prolonged Grief Disorder studies →

Open to participants now

4 of the 15 studies in Prolonged Grief Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Prolonged Grief Disorder studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prolonged Grief Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).

Read the detailed description

The study aims to investigate whether a single dose of 25 mg psilocybin can reduce the symptoms of grief and trauma associated with Prolonged Grief Disorder (PGD). It is hypothesized that psilocybin will significantly reduce the symptoms of PGD, and that the treatment will facilitate subjective mystical, spiritual, or insightful experiences, which in turn may contribute to the alleviation of grief and trauma symptoms. Neuroimaging will be used to help researchers better understand the relationship between grief and brain functions, comparing pre- and post-dose scans. Participants will undergo two MRI (magnetic resonance imaging) where they are asked to look at images (this is called a functional MRI or fMRI).

03

Conditions studied

  • Prolonged Grief Disorder

Keywords

  • prolonged grief disorder
  • psilocybin
  • psychedlic-assisted treatment
  • psilocybin-assisted therapy
  • grief
  • grief disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 years old up to and including 65 years of age
  • Negative UDS results for illicit drugs at screening and prior to each drug administration session
  • Consent to all study procedures
  • Have an existing diagnosis of Prolonged Grief Disorder. May also be determined to have Complicated Grief Disorder without official diagnosis as determined by PI or designate based on DSM V criteria
  • Score of greater than 25 on the Inventory of Complicated Grief
  • Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session
  • People of that are sexually active must agree to continue or initiate practice of a highly effective means of , alone or in combination with another, throughout the study. Highly effective options are: implants, intrauterine devices (IUD), and sterilization. Exclusive use of condoms is not effective.
  • Be judged by study team clinicians to be at low risk for suicidality as determined by MINI, Columbia Suicide Severity Scale, and the Patient Health Questionnaire-9.
  • Concurrent psychotherapy or pharmacotherapy with SSRIs, SNRIs, and/or bupropion (\< 300 mg bupropion) is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study
  • Be otherwise medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an (ECG), urine beta-HCG, and urine toxicology screen
  • Participant must agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that they consume on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, they must agree not to do so on session days
  • Agree not to take any PRN medications on the mornings of drug sessions
  • Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration
  • Agree that for one week before each drug session, participant will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals
  • Willingness and ability to remain within the observation room for the duration of the study visits up to 10 hours
  • Willingness and ability to follow study protocol as directed by research staff
  • Willing and able to attend all sessions in the study and complete follow up assessments
  • Fluent in English
  • Ability to provide one photo of a deceased loved one and one photo of a living loved one, as required for the grief elicitation task.

Exclusion criteria

Exclusion Criteria:

General medical exclusion criteria:

  • Previous use of a psychedelic drug may be exclusionary depending on frequency, context, and participant safety as determined by the PI or designate.
  • Person who is pregnant, nursing, or planning to get pregnant determined at screening and before drug session by urine test or self-report
  • People of that are sexually active who are not practicing an effective means of
  • Cardiovascular conditions: coronary artery disease, stroke, angina, a abnormality (e.g., atrial fibrillation), prolonged (i.e., QTc > 450 msec), heart valve, or in the past year.
  • History of head trauma with neurological deficit; seizures, or neurologic disorders including cerebrovascular disease, epilepsy, or neurogenerative diseases
  • Type 1 diabetes
  • \<18
  • Currently taking on a regular (e.g., daily) basis any antidepressant medications other than SSRIs, SNRIs, or bupropion, or any other medications that have a primary centrally-acting serotonergic effect, including MAOIs. Bupropion dosage must be \< 300 mg in order to be included
  • Nicotine dependence that would be incompatible with remaining in study area for the entirety of the visit
  • Prescribed or illicit use of benzodiazepines or opioids within 4 weeks prior to screening
  • Baseline blood pressure greater than 139/79 (after repeat measures) unless stable with medication as determined by PI or PI designate
  • Taking any muscle relaxers, antihistamines, or other medications known to cause lethargy or impair cognitive ability within one day prior to psilocybin session
  • Serious medical comorbidity requiring medical intervention or close supervision
  • History of claustrophobia
  • Any court mandated or legal restrictions that would impair the participant from attending all visits
  • Inability to follow and comply with all study procedures
  • Deemed unable to meaningfully or safely participate in the study
  • Any legal judgement toward subject determined to interfere with study attendance or jeopardize compliance with study protocol determined by PI or designate
  • Individuals who are unable to undergo MRI as determined by MRI pre-screening.

General psychiatric exclusion criteria:

  • Score of less than 25 on the Inventory of Complicated Grief
  • Severe psychiatric disorder (other than depression) within 6 months or lifetime history of serious psychiatric or neurological disorders, including bipolar disorder, or active psychosis
  • Clinically significant suicidal ideation (e.g., with strong intent or means) within past 6 months or lifetime history of suicide attempt based on the MINI, Patient Health Questionnaire-9 or Columbia-Suicide Severity Scale. At any point during the study, a participant may be withdrawn from the study for concerns of suicidality and provided follow-up care by our team or a referral to care if needed.
  • Current or past history of meeting criteria for schizophrenia spectrum or other psychotic disorders, or bipolar I disorder
  • Current or previous history within one year of meeting DSM-5 criteria for a moderate or severe alcohol, or other drug use disorder (excluding tobacco, caffeine, and cannabis)
  • Nicotine dependence that would be incompatible with an individual to be nicotine free for 8-10 hours on a psilocybin session day
  • Have a first degree relative with schizophrenia or other psychotic disorders (except substance/medication-induced or due to another medical condition), or bipolar I disorder
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Open-label, single arm trial

    25 mg psilocybin administered to each participant

    Drug: Psilocybin 25 mg · Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI)

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    25 mg psilocybin administered to each participant in single arm, open-label trial

  • Diagnostic testFunctional Magnetic Resonance Imaging (fMRI)

    There are two "fMRIs" (functional magnetic resonance imaging) that take place 1-14 days before and 1-14 days after psilocybin administration.

06

What researchers measure

Primary outcomes

  1. Recruitment Rate

    Number of participants enrolled divided by number screened over the recruitment period.

    Time frame: Through end of enrollment period

  2. Dropout Rate

    Proportion of enrolled participants who withdraw or are lost to follow-up prior to completing the 6-month assessment.

    Time frame: Baseline to 6-month Follow-up

Secondary outcomes

  1. Change in Prolonged Grief Disorder Symptoms (ICG)

    Change in the Inventory of Complicated Grief (ICG) is a 19-item scale assessing prolonged grief symptoms. Scores range from 0 to 76, with higher scores indicating greater symptom severity.

    Time frame: Baseline (Visit 0 - Screening) to 6-month Follow-up

  2. Change in PTSD Symptoms (DTS)

    Change in Davidson Trauma Scale (DTS) total score; range 0-136; higher scores indicate more severe PTSD symptoms.

    Time frame: Baseline (Visit 0 Screening) to 6-month Follow-up

  3. Mystical Experience (MEQ)

    Change in Mystical Experiences Questionnaire (MEQ-30) mean score; range 0-5; higher scores indicate greater mystical-type experience.

    Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up

  4. Altered States of Consciousness (5-D ASC)

    Change in 5-Dimensions of Altered States of Consciousness score; range 0-100%; higher percentages indicate greater altered-state intensity.

    Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up

  5. Awe Experience (AWE-S)

    Change in Awe Experience Scale mean score; range 1-7; higher scores indicate greater awe.

    Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up

  6. Challenging Experiences (CEQ)

    Change in Challenging Experiences Questionnaire mean score; range 0-5; higher scores indicate more intense challenging experiences.

    Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up

  7. Psychological Flexibility (AAQ-II)

    Change in Acceptance and Action Questionnaire-II total score; range 7-49; higher scores indicate greater psychological inflexibility.

    Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up

  8. Closeness to Others (IOS)

    Change in Inclusion of Others in the Self single-item score; range 1-7; higher scores indicate greater perceived interpersonal closeness.

    Time frame: Baseline (Visit 0 - Screening) to 6-month Follow-up

  9. Meaning in Life (MIL)

    Change in Meaning in Life Questionnaire Presence and Search subscales; each subscale range 5-35; higher scores indicate greater presence of meaning (Presence) or search for meaning (Search).

    Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up

  10. Psychological Insight (PIQ)

    Change in Psychological Insight Questionnaire mean score; range 0-5; higher scores indicate greater psychological insight.

    Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up

  11. Personality Traits (NEO-FFI)

    Change in the NEO Five-Factor Inventory (NEO-FFI) is a 60-item measure assessing five personality domains: Neuroticism, Extraversion, Openness, Agreeableness, and Conscientiousness. Each domain score ranges from 0-48, with higher scores indicating greater expression of the corresponding personality trait.

    Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Mar 24, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06724289
Collaborators
Tiny Blue Dot Foundation, Texas Tech University
Responsible party
Jennifer Kim Penberthy (PhD, ABPP, University of Virginia) — Principal investigator
First posted
Dec 9, 2024
Start date
Mar 24, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Fatma Wise, PhD
Contact
uvagrieftrial@uvahealth.org
(434) 243-0568
Madison Focht
Contact
uvagrieftrial@uvahealth.org
Jennifer K Penberthy, PhD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion